

- Dub*
- a) the amino acid sequence of SEQ ID NO:1,
 - b) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1, and
 - c) an immunogenic fragment of the amino acid sequence of SEQ ID NO:1.
-

18. A polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:1.

19. A composition comprising a polypeptide of claim 18 and with a suitable pharmaceutical carrier.

Dub 2

20. A composition comprising a polypeptide of claim 1 and with a suitable pharmaceutical carrier.

Dub 2

25. A polypeptide of claim 1 which comprises a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1.

Dub 3

26. A composition comprising a polypeptide of claim 25 and a suitable pharmaceutical carrier.

REMARKS

The Invention

Applicants' invention comprises, *inter alia*, a novel human prostate-associated kallikrein protein (hereinafter referred to as HPAK), the naturally-occurring amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:1, as well as biologically-active and antigenically-active fragments of SEQ ID NO:1. HPAK, and variants thereof, are useful in the diagnosis of acquired and inherited disease, expression profiling, and drug development. HPAK shares chemical and structural homology with human pancreatic kallikrein (GI 186653). In particular, HPAK shares 54% identity with GI 186653, including the conserved amino acid residues for serine protease activity, H₆₅ D₁₁₃, and S₂₀₆, as well as D₂₀₀ which is likely to confer on HPAK chymotrypsinogen-like activity, and 10 conserved cysteine residues (31, 50,